It is not infrequent that patients with different cancers are affected by bodily organ
dysfunction. Factors such as comorbidities, prior anticancer therapies and tumor-related …

As with other therapeutic areas, the need to understand the disposition of antineoplastic
drugs in patients who have hepatic and renal dysfunction is paramount during drug …

In the past, patients with cancer, who also have hepatic or renal dysfunction, have carried a
triple burden. Not only have they suffered from cancer and organ dysfunction, but until …

TO THE EDITOR: The article by Beumer et al 1 addressed the effect of renal impairment on
the toxicity of anticancer compounds tested in phase I trials over three decades, and the …

Abstract The US Food and Drug Administration (FDA) issued a guidance document in 2010
on pharmacokinetic (PK) studies in renal impairment (RI) on the basis of observations that …

Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …

The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review …

e13518 Background: Anticancer drug dosing recommendations in kidney dysfunction are
often empirical, based on non-standardised creatinine assays calculated via the Cockcroft …

Cancer patients with adequate hepatic or renal function are typically studied in clinical trials.
Since most anticancer agents are cleared via hepatic or renal mechanisms, dose …

e23002 Background: Accurate assessment of renal function is critical in oncology clinical
trials. Many anti-cancer agents are renally excreted or cleared, and impaired kidney function …